ASCENDIS PHARMA A/S
ASNDNASDAQTrading Snapshot
- Day Range
- $243.45 – $249.85
- 52-Week Range
- —
- Volume (shares)
- 660,087
- Avg Volume (shares)
- —
- Shares Outstanding
- 66.4M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- $692M
- Last Q Revenue
- $345M
- P/E Ratio
- 18.6
- P/S Ratio
- 13.2x
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- +2.7%
ASCENDIS PHARMA A/S
ASND
StockOtter · stockotter.spaceAbout ASCENDIS PHARMA A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026
Ascendis Pharma A/S’s (ASND) “Overweight” Rating Reaffirmed at Cantor Fitzgerald
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They presently have a
Ascendis Pharma: Back To Full Independence
Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved products—Skytrofa, Yorvipath, and